- Home
- SGMT vs SRV Comparison
SGMT vs SRV Comparison
Compare SGMT & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- SRV
- Stock Information
- Founded
- SGMT 2006
- SRV 2007
- Country
- SGMT United States
- SRV United States
- Employees
- SGMT N/A
- SRV N/A
- Industry
- SGMT
- SRV Finance Companies
- Sector
- SGMT
- SRV Finance
- Exchange
- SGMT Nasdaq
- SRV Nasdaq
- Market Cap
- SGMT 128.5M
- SRV N/A
- IPO Year
- SGMT 2023
- SRV N/A
- Fundamental
- Price
- SGMT $3.35
- SRV $44.11
- Analyst Decision
- SGMT Strong Buy
- SRV
- Analyst Count
- SGMT 6
- SRV 0
- Target Price
- SGMT $25.67
- SRV N/A
- AVG Volume (30 Days)
- SGMT 315.0K
- SRV 33.9K
- Earning Date
- SGMT 03-12-2025
- SRV 01-01-0001
- Dividend Yield
- SGMT N/A
- SRV 13.38%
- EPS Growth
- SGMT N/A
- SRV N/A
- EPS
- SGMT N/A
- SRV N/A
- Revenue
- SGMT N/A
- SRV N/A
- Revenue This Year
- SGMT N/A
- SRV N/A
- Revenue Next Year
- SGMT N/A
- SRV N/A
- P/E Ratio
- SGMT N/A
- SRV N/A
- Revenue Growth
- SGMT N/A
- SRV N/A
- 52 Week Low
- SGMT $2.39
- SRV $30.73
- 52 Week High
- SGMT $7.38
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- SGMT 44.81
- SRV 45.37
- Support Level
- SGMT $3.70
- SRV $43.59
- Resistance Level
- SGMT $4.24
- SRV $45.15
- Average True Range (ATR)
- SGMT 0.23
- SRV 0.85
- MACD
- SGMT 0.04
- SRV 0.16
- Stochastic Oscillator
- SGMT 45.70
- SRV 41.79
Stock Price Comparison Chart: SGMT vs SRV
■ SGMT
■ SRV
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Share on Social Networks:
0